Summary of percentage (%) of classified responders and non-responders according
to secondary outcomes of weeks 6–12 versus that by the longitudinal primary
outcome of weeks 6–12.
Overall
ponders on the basis of the secondary outcomes for the topiramate
and placebo groups, respectively. In contrast, of those classified as
non-responders according to the primary outcome, only 35.9% and
11.1% were classified as non-responders on the basis of secondary
outcomes in the topiramate and placebo groups, respectively. It is
clear that the two classifications based on the primary outcome and
the secondary outcomes of weeks 6–12 agreed better in the topiramate
group than in the placebo group. On average, if a topiramate
recipient was classified as a responder as judged by the primary
outcome, the subject was 10 times more likely to be classified as a
responder according to the secondary outcomes
% of responders and
non-responders based on the
secondary outcomes among
those classified as such by the
primary outcome